{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053653","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.788048+00:00","generated_at":"2026-06-09T22:46:19.515125+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Monte Rosa signs $50M upfront Roche collaboration for MGDs; MRT-2359 shows early efficacy","bullets":["Upfront payment of $50M from Roche; potential milestones >$2B for initial oncology/neurology targets.","Roche gains exclusive license after pre-clinical; Monte Rosa leads discovery on initial targets.","MRT-2359 interim data: ~60% GSPT1 reduction in tumors; 2 partial responses in biomarker-positive patients.","Safety profile supports further development; Grade 4 AEs at 2mg were transient, no discontinuations.","Monte Rosa retains full ownership of pipeline; joint research committee governs collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053653","json":"https://secwatch.observer/filing/0000950170-23-053653.json","markdown":"https://secwatch.observer/filing/0000950170-23-053653.md","text":"https://secwatch.observer/filing/0000950170-23-053653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/0000950170-23-053653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/glue-20231017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:46:19.515125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc08b59660c18879aaea4cc2189d8c0227e69739","claim":"Monte Rosa Therapeutics, Inc. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. valued at upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston (effective 2023-10-16).","evidence_excerpt":"On October 16, 2023, Monte Rosa Therapeutics AG (“Monte Rosa AG,” hereinafter the “Company”), a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc., F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US” and together with Roche Basel, “Roche”) entered into a Collaboration and License Agreement (the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023053653/0000950170-23-053653-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc."},{"label":"Value","value":"upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston"},{"label":"Effective","value":"2023-10-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}